OLBA HEALTHCARE HOLDINGS, Inc. (2689) AI Stock Analysis

• Market Cap: ¥12.47B
• Dividend Yield: 3.91%
• Average Volume (3M): 2.62K
• Price to Earnings (P/E): 8.4
• Beta (1Y): 0.27
• Revenue Growth: 3.49%
• EPS Growth: -4.39%
• Country: JP
• Employees: 1,354
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 83.95
• Shares Outstanding: 6,250,000
• 10 Day Avg. Volume: 2,280
• 30 Day Avg. Volume: 2,620
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,224.00
• Price Target Upside: 9.50% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 69 Neutral
• Price Target: ¥2,224.00 ▲(9.50% Upside)

OLBA HEALTHCARE HOLDINGS, Inc. demonstrates a strong financial position with solid revenue growth and stable operational performance. The stock is attractively valued with a low P/E ratio and a high dividend yield. However, technical indicators suggest a neutral trend, which tempers the overall score.

OLBA HEALTHCARE HOLDINGS, Inc. Business Overview & Revenue Model

Company Description

OLBA HEALTHCARE HOLDINGS, Inc. provides various solutions to medical institutions, universities, corporate research institutes, individuals, and long-term care facilities in Japan. The company's medical equipment business engages in the wholesale of artificial joints, pacemakers, coronary stents, steel instruments, and ultrasonic scalpels; and diagnostic imaging equipment, such as MRI and CT to respirators, intraoperative monitors, and surgical lights. It also offers reagents and equipment for genetic research, cell culture, and protein analysis; automatic analyzers for biochemistry, immunity, and blood; and test reagents, as well as undertakes services for DNA analysis in the field of life sciences. The company's Supply Processing and Distribution business provides goods management, information management, and purchase management services. Its Nursing care products business engages in the rental of nursing care equipment; sale of welfare equipment, such as portable toilets and bathing equipment; and operation of long-term care reform, a comfortable stay at home. The company was formerly known as Kawanishi Holdings, Inc. and changed its name to OLBA HEALTHCARE HOLDINGS, Inc. in January 2021. OLBA HEALTHCARE HOLDINGS, Inc. was founded in 1921 and is headquartered in Okayama, Japan.

How the Company Makes Money

OLBA HEALTHCARE HOLDINGS generates revenue through multiple streams, primarily from the sale of its pharmaceutical products and medical devices. The company has established partnerships with healthcare providers, hospitals, and pharmacies, allowing it to distribute its offerings widely. Additionally, OLBA may engage in research and development collaborations with other firms to innovate and bring new products to market, which can lead to licensing and royalty agreements that contribute to its revenue. The company's ability to leverage its technological advancements and maintain strong relationships within the healthcare ecosystem is crucial for sustaining its earnings.

OLBA HEALTHCARE HOLDINGS, Inc. Financial Statement Overview

Summary

OLBA HEALTHCARE HOLDINGS, Inc. shows strong revenue growth and stable operational performance. The balance sheet is solid with a healthy equity base and improving debt management. Cash flow metrics show some volatility, but recent trends are encouraging. Overall, the company is in a good financial position, though careful attention to debt levels and cash flow alignment is advisable.

Income Statement

OLBA HEALTHCARE HOLDINGS, Inc. has demonstrated strong revenue growth with a 0.87% increase in the latest year. The gross profit margin is healthy, reflecting efficient cost management. However, the net profit margin has slightly decreased, indicating some pressure on profitability. The EBIT and EBITDA margins are stable, suggesting consistent operational performance.

Balance Sheet

The company maintains a solid equity base with a debt-to-equity ratio that has improved over time, indicating prudent financial management. Return on equity is strong, reflecting effective use of shareholder funds. The equity ratio is robust, showcasing a stable financial position. However, the increase in total debt over the years could pose a potential risk if not managed carefully.

Cash Flow

Operating cash flow has shown volatility, but recent improvements are promising. The free cash flow growth is positive, although the free cash flow to net income ratio indicates room for improvement in cash generation relative to earnings. The operating cash flow to net income ratio suggests a need for better alignment between cash flows and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	121.64B	122.70B	118.56B	110.47B	107.96B	112.98B
Gross Profit	13.73B	13.91B	13.60B	12.95B	12.50B	11.60B
EBITDA	2.47B	2.59B	2.83B	2.68B	2.56B	1.94B
Net Income	1.32B	1.43B	1.50B	1.41B	1.54B	989.37M
Balance Sheet
Total Assets	47.02B	45.87B	43.24B	40.88B	39.97B	36.56B
Cash, Cash Equivalents and Short-Term Investments	2.98B	3.47B	2.73B	2.40B	3.19B	2.16B
Total Debt	3.70B	2.95B	1.63B	1.92B	1.28B	1.96B
Total Liabilities	35.24B	33.56B	31.86B	30.55B	30.88B	28.43B
Stockholders Equity	11.77B	12.26B	11.37B	10.33B	9.09B	8.13B
Cash Flow
Free Cash Flow	0.00	181.25M	1.61B	-910.52M	1.97B	2.49B
Operating Cash Flow	0.00	1.63B	2.08B	-659.52M	2.42B	3.13B
Investing Cash Flow	0.00	-1.64B	-673.03M	-306.25M	-211.81M	-630.38M
Financing Cash Flow	0.00	686.95M	-1.09B	175.94M	-1.17B	-2.26B

OLBA HEALTHCARE HOLDINGS, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2031.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2689, the sentiment is Negative. The current price of 2031 is below the 20-day moving average (MA) of 2034.55, below the 50-day MA of 2041.84, and above the 200-day MA of 2001.31, indicating a neutral trend. The MACD of 0.24 indicates Negative momentum. The RSI at 47.51 is Neutral, neither overbought nor oversold. The STOCH value of 26.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2689.

OLBA HEALTHCARE HOLDINGS, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9265	76 Outperform	7.89B	12.39	0.00%	1.98%	4.76%	9.55%
3417	75 Outperform	19.34B	6.75	8.52%	1.86%	3.70%	37.00%
3151	71 Outperform	58.85B	9.10	6.90%	3.39%	2.22%	21.19%
3183	70 Outperform	38.99B	18.47	0.00%	3.86%	5.81%	8.10%
4350	70 Outperform	14.67B	12.14	7.77%	2.46%	5.93%	-36.11%
2689	69 Neutral	¥12.47B	8.42		3.91%	3.49%	-4.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

OLBA HEALTHCARE HOLDINGS, Inc. Corporate Events

OLBA HEALTHCARE HOLDINGS Reports Fiscal Year 2025 Financial Results

OLBA HEALTHCARE HOLDINGS, Inc. reported its consolidated financial results for the fiscal year ended June 30, 2025, showing a rise in net sales by 3.5% to ¥122,702 million. However, the company experienced a decline in operating profit and ordinary profit by 11.1% and 12.6%, respectively. The financial results indicate challenges in maintaining profitability despite increased sales, with a notable decrease in comprehensive income by 17.7%. The company also announced a dividend of ¥80.00 per share, consistent with the previous year, reflecting a commitment to shareholder returns amidst fluctuating financial performance.